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ABSTRACT OF THE DISSERTATION 
 
ROLE OF CALCIUM IN INFLAMMATION: RELEVANCE TO  
ALZHEIMER’S DISEASE 
      by 
 
Amita Quadros 
Florida International University, 2007 
Miami, Florida 
                                   Professor Ophelia Weeks, Major Professor 
 Alzheimer’s disease (AD) is neuropathologically characterized by excessive beta 
-amyloid (Aβ) plaques and neurofibrillary tangles composed of hyperphosphorylated tau 
in the brain. Although the etiology of genetic cases of AD has been attributed to 
mutations in presenilin and amyloid precursor protein (APP) genes, in most sporadic 
cases of AD, the etiology is still unknown and various predisposing factors could 
contribute to the pathology of AD. Predominant among these possible predisposing 
factors that have been implicated in AD are age, hypertension, traumatic brain injury, 
diabetes, chronic neuroinflammation, alteration in calcium levels and oxidative stress. 
Since both inflammation and altered calcium levels are implicated in the pathogenesis of 
AD, we wanted to study the effect of altered levels of calcium on inflammation and the 
subsequent effect of selective calcium channel blockers on the production of pro-
inflammatory cytokines and chemokines.  Our hypothesis is that Aβ,  depending on it 
conformation, may contribute to altered levels of intracellular calcium in neurons and 
glial cells. We wanted to determine which conformation of Aβ was most pathogenic in 
terms of increasing inflammation and calcium influx and further elucidate the possibility 
 vi 
of a link between altered calcium levels and inflammation. In addition, we wanted to test 
whether calcium channel blockers could inhibit the inflammation mediated by the most 
pathogenic form of Aβ,  by antagonizing the calcium influx triggered by Aβ.  
 Our results in human glial and neuronal cells demonstrate that the high molecular 
weight oligomers are the most potent at stimulating the release of pro-inflammatory 
cytokines IL-6 and IL-8 as well as increasing intracellular levels of calcium compared to 
other conformations of Aβ. Further, L-type calcium channel blockers and calmodulin 
kinase inhibitors are able to significantly reduce the levels of IL-6 and IL-8.  These 
results suggest that Aβ−induced alteration of intracellular calcium levels contributes to its 
pro-inflammatory effect. 
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 1 
    CHAPTER ONE 
INTRODUCTION:  
1.1. NEUROPATHOLOGICAL FEATURES OF ALZHEIMER’S DISEASE 
 Alzheimer’s disease (AD) a protein misfolding disease named after Alois 
Alzheimer, is the major cause of dementia in the elderly in Western countries. The 
neuropathology of AD brains is characterized by the progressive accumulation of 
intracellular neurofibrillary tangles (NFT) and extracellular parenchymal senile plaques 
(Wilcock and Esiri1982). The tangles consist of hyperphosphorylated tau while the 
plaques comprise of beta-amyloid (Aβ) peptides (Jellinger and Bancher1998). Biological 
markers like the presence of Aβ and tau in the cerebrospinal fluid (CSF) of AD patients 
provide an important tool in the diagnosis of the disease but they are not foolproof as 
other neurodegenerative diseases also show the presence of Aβ and tau in the CSF 
(Hampel et al. 2003). Reports have shown that compared to normal control patients, 
brains of AD patients exhibit significant cortical synaptic loss, Aβ deposition, NFT 
formation, and inflammation (Lue et al.1996). Although senile plaques and NFTs are the 
neuropathological hallmarks of AD, significant microvascular pathology including 
reduced vascular density, atrophic vessels, and vascular amyloid deposits as cerebral 
amyloid angiopathy (CAA) have also been well described as part of AD pathology 
(Hashimura et al.1991, Buee et al.1994, Kalaria and Hedera 1996, Jeynes and Provias 
2006). For over a decade it has been thought that Aβ may play an important role in 
mediating the initial pathogenic events in AD since all the mutations associated with 
familial forms of AD affect processing of Aβ from its substrate amyloid precursor protein 
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(APP) (Selkoe 1996). The familial cases of AD are mainly due to genetic mutations in the 
presenilin genes (PS1 and PS2) and in the APP gene. The APOE ε4 allele is also reported 
as a genetic risk factor for AD (Wilhelmus et al. 2005). The two leading hypotheses for 
AD etiology are the ‘amyloid cascade hypothesis’ implicating Aβ as the central mediator 
while the ‘neuronal cytoskeletal degeneration hypothesis’ implicates tau as the prime 
suspect in causing AD. Other reports also implicate α-synuclein a synaptic protein 
implicated in Lewy bodies to also be responsible for AD pathology (Wirths and Bayer 
2003).  
 
1.1.1. AMYLOID CASCADE HYPOTHESIS: 
 According to the ‘amyloid cascade’ hypothesis that was initiated in the 1980’s, 
Aβ, the major protein present in plaques is produced as a result of the endoproteolytic 
cleavage of APP by beta (β) and gamma (γ)  secretases, and Aβ aggregates deposited 
around neurons as senile plaques (Russo et al. 2002, Hardy and Higgins 1992, Glenner 
and Wong 1984). The processing of APP results in the formation of Aβ that under normal 
circumstances is degraded by neprilysin or other proteases and then eliminated. In 
neurons of AD patients as compared to controls there may be a decrease in alpha 
(α) secretase activity over β-secretase activity resulting in increased Aβ production or 
lack of neprilysin/clearance mechanisms to degrade Aβ and clear it from the body (Buee 
et al. 1994, Rojas-Fernandez et al. 2002, Iwata et al. 2001). The two major enzymes, 
which enable the generation of Aβ from APP, are the β and γ secretases. β-secretase 
cleaves APP at the N-terminus to release sAPPβ, a 100-kD soluble N-terminal fragment 
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and C99, a 12-kD C-terminal fragment which remains membrane bound (Benjannet et al. 
2001). Cleavage by α-secretase produces sAPPα and C83, a 10-kD membrane-bound C-
terminal fragment. Both C-terminal fragments, C99 and C83, then become the substrate 
for one or more γ-secretases that cleave the fragments within their transmembrane 
domains, leading to the release and secretion of Aβ and the nonpathogenic p3 peptide, 
respectively (Neve et al. 2000). Hence, preventing the β- secretase cleavage and/or 
enhancing α-secretase activity would decrease the formation of Aβ (Citron 2002, Vassar 
2002, Tyler et al. 2002). Many studies are being carried out in vitro and in vivo to 
determine if blocking β-secretase activity may reduce the pathology associated with AD. 
The relative amount of β versus α secretase cleavage is higher in AD compared to 
controls and the major β-secretase is BACE 1 over BACE 2 (Zhao et al. 2007). Studies 
have shown that the subcellular localization and phosphorylation of BACE affects its 
cleavage specificity for APP (Walter et al. 2001).  
Elucidation of the proteolytic processing of APP resulting in the release of 
Aβ  revealed that γ-secretase that cleaves intramembranous APP may most likely be 
presenilins (Xu et al. 2002) since mutations in PS resulted in early-onset Alzheimer’s 
disease. Also the fact that PS could specifically influence the C-terminal cleavage of Aβ, 
in particular the Aβ1−40/1-42 ratio was another reason for researchers to believe that PS 
could be the elusive γ-secretase enzyme. Other researchers disagreed with this theory 
because PS and APP are located in different secretory compartments, and nicastrin also 
plays an important role in γ-secretase activity (Li et al. 2003). Researchers have been 
trying to elucidate a possible mechanism of APP cleavage by presenilin (Annaert et al. 
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1999). There is an ongoing debate if PS1 is the actual γ-secretase due to the difference in 
subcellular localization of PS1 and APP and also because γ-secretase is composed of 
other proteins like nicastrin, PEN-2, Aph-1(Cupers et al. 2001).  
Aβ peptide in AD brains is composed of 39-43 amino acids. Data suggest that 
soluble forms of Aβ correlate better with the severity of dementia observed in AD 
patients than aggregated forms (Mclean et al. 1999, Kim et al. 2003).  Several isoforms of 
Aβ exist, however Aβ1-40 is the more soluble isoform compared to Aβ1-42 which 
aggregates more rapidly. However in AD brains, the amount of Aβ soluble oligomers 
found is elevated compared to control brains. Soluble oligomers are also referred to as 
amyloid-beta derived diffusible ligands (ADDLs). There are two pools of Aβ in AD 
brains, one pool with soluble forms include monomers/dimers and solube oligomers and 
the other pool of aggregated insoluble forms of Aβ form the senile plaques and give rise 
to cerebral amyloid angiopathy (CAA). Several studies indicate that Aβ undergoes 
conformational changes when it interacts with the cell membrane resulting in Aβ 
assuming functional properties of an ion channel (Bhatia et al. 2000). It has been well 
established that the different forms of Aβ induce neurotoxicity. However, the exact 
mechanism of action for this neurotoxicity has not been established and is still under 
investigation by various research groups. One of the mechanisms by which Aβ mediates 
toxicity is by forming ion channels (Lin et al. 2001). Researchers speculate that this 
neurotoxicity mediated by Aβ due to its ion-channel forming abilities is because Aβ 
undergoes conformational changes when it interacts with the lipid in the cell membrane 
(Arispe et al. 1993, Kayed et al. 2004).  
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1.1.2. CYTOSKELETON HYPOTHESIS:  
 According to the ‘cytoskeleton hypothesis’ tau is implicated as the prime suspect 
in causing AD. Weingarten and colleagues first discovered a microtubule-associated 
protein tau (MAPT) in 1975 (Weingarten et al. 1975). The major function of tau in the 
CNS is in the stabilization of microtubules in neurons and tau might be involved in the 
establishment and maintenance of neuronal polarity. The tau gene located on human 
chromosome 17q21 in the human genome, contains 16 exons with the major tau isoform 
being encoded by 11 exons (Goedert et al. 1989, Spillantini and Goedert 1998). 
Alternative pre-mRNA splicing of exons 2, 3 and 10 in the single tau gene results in the 
formation of six different isoforms in the adult human brain (Buee et al. 2000). These 
isoforms ranging from 352-441 amino acids are responsible for the modulation of tau 
function and are characterized by the presence of three (3R tau) or four (4R tau) tandem 
repeats of 31-32 amino acids located in the carboxy terminal end which is also the 
microtubule binding domain of tau (Goedert and Jakes 2005).  In adult human brain the 
ratio of 3R tau to 4R tau is approximately 1 and this balance is disrupted in the case of 
tau mutations associated with exon 10 (D’Souza and Schellenberg 2005). Various kinases 
and phosphatases are involved in the regulation of tau phosphorylation that occurs at a 
number of serine, threonine and proline residues (Butler and Shelanski 1986, Ferrer et al. 
2005).  
 Tau protein has been used in various configurations as a diagnostic marker of 
degenerative changes in the CNS. Tau hyperphosphorylation is at the crux of most 
tauopathies since hyperphosphorylation dissociates tau from microtubules, destabilizes 
them and forms paired helical filaments (PHF) in vitro (Lindwall and Cole 1984, Alonso 
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et al. 1994). Tau phosphorylation is regulated by an exquisite equilibrium between kinase 
and phosphatase activities. An imbalance of these two enzymatic processes can result in 
abnormal hyperphosphorylation of tau and generation of PHF. Mutations in the tau gene 
and tau hyperphosphorylation have been observed in many neurodegenerative diseases as 
well as in senescent brains. Neurodegenerative diseases of note include Pick’s disease, 
AD, Frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), 
progressive supranuclear palsy (PSP), corticobasal degeneration, Niemann Pick’s disease, 
etc. These diseases are all referred to as tauopathies since they all share a common 
pathology which is aggregated tau. 
Tau is a major constituent of microtubules, and since microtubules offer 
stabilization to neurons, tau hyperphosphorylation and subsequent aggregation may be 
central in the neurodegeneration observed in AD (Alonso et al. 2001). Studies suggest 
that cognitive deterioration occurs only after the development of neurofibrillary tangles 
with hyperphosphorylated tau. Tau hyperphosphorylation in AD results in the reduced 
ability of tau to bind to microtubules. In AD, tau is hyperphosphorylated at 30 specific 
amino acid sequences throughout its 441 amino acids (Gong et al.  2005). In vitro studies 
suggest that increases in Aβ production may potentiate tau phosphorylation by activation 
of kinases such as glycogen synthase kinase-3 (GSK-3) (Phiel et al. 2003). 
Phosphorylated tau protein at Threonine 231 is seen in postmortem brain tissue of 
patients with AD and can be detected in CSF (Buerger et al. 2002). In vitro studies with 
cultured cells have shown that Aβ induced tau phosphorylation is neurotoxic to cultured 
cells (Busciglio et al. 1995). Other supportive evidence for the tau hypothesis in AD can 
be found from studies with transgenic mouse models of AD that overexpress mutant APP 
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or PS. These animals develop senile plaques with age, but they fail to develop NFTs and 
exhibit little neuronal loss (Holcomb et al. 1998). Researchers supporting the tau 
hypothesis claim that tau alone is sufficient to cause dementia and neurodegenration since 
mutations in tau cause frontotemporal dementia (FTD). In addition, studies with 
transgenic mice having the ‘Swedish’ mutation (TgAPPsw), that causes early onset AD 
in humans, reveal the presence of abundant Aβ deposits that are visible beginning at 9 
months of age (Duff et al. 1996). However, these mice do not show substantial 
neurodegeneration despite the presence of Aβ plaques. Although amyloid and tau are 
often present in the same brain areas, namely hippocampus and entorhinal cortex, a 
mechanistic link between them has yet to be established. Recent data suggest that Aβ is 
upstream of tau and that Aβ deposition induces accumulation of tau resulting in memory 
impairment (Gotz et al. 2004, Ribe et al. 2005). Hence there could be a possible 
interaction between amyloid and tau which is responsible for the pathogenesis associated 
in AD. However, there is no evidence to date demonstrating that abnormal tau 
phosphorylation or accumulation causes amyloid deposition. 
 
1.1.3. NEUROVASCULAR HYPOTHESIS:  
 Another recent hypothesis that is gaining momentum with regards to the 
pathogenesis of AD is the neurovascular hypothesis. Due to the link between AD and 
atherosclerosis (Kalback et al. 2004) neurovascular dysfunction is believed to be 
responsible for the cognitive decline and neurodegeneration observed in AD. The 
neurovascular unit in the brain consists of astrocytes, neurons, pericytes in close 
association with the vascular endothelium to maintain cerebral homeostasis and serve as 
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the first line of defense against pathogenic factors (Frontczak-Baniewicz and Walski 
2006). According to the neurovascular hypothesis for AD faulty clearance of Aβ across 
the blood-brain barrier (BBB) together with aberrations in angiogenesis results in brain 
hypoperfusion and neurovascular inflammation (Zlokovic 2005, Zlokovic et al. 2005). 
The BBB regulates Aβ transport via two main receptors, the low density lipoprotein 
receptor related protein 1 (LRP1) and the receptor for advanced glycation end products 
(RAGE) (Deane and Zlokovic 2007). The RAGE receptor is thought to be a primary 
transporter of Aβ across the BBB into the brain from the systemic circulation, while the 
LRP-1 mediates transport of Aβ out of the brain (Donahue et al. 2006). The RAGE 
receptor is a member of the immunoglobulin superfamily and exists in three major 
isoforms in the brain. They are expressed in neurons, microglia, astrocytes, pericytes, 
smooth muscle cells and cerebral endothelial cells. The adverse consequences of RAGE 
interaction with Aβ include perturbation of neuronal properties and functions, 
amplification of glial inflammatory responses, elevation of oxidative stress and 
amyloidosis, increased Aβ influx at the BBB and vascular dysfunction (Lue et al. 2005). 
Previous studies on microglia demonstrate that binding of Aβ to RAGE receptor results 
in the production of macrophage-colony stimulating factor (M-CSF) via the NFkB 
dependent pathway thereby suggesting that inflammation is one of the mechanisms 
involved in AD neurotoxicity (Du et al. 1997). The neurovascular hypothesis in AD 
suggests that Aβ causes a reduction in cerebral blood flow (CBF) due to vasoconstriction 
of cerebrovessels. Aβ also causes regression of cerebrovessels due to faulty mechanisms 
involving angiogenesis and subsequent activation of glial cells resulting in 
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neuroinflammation. Hence therapies aimed at clearance of Aβ from the brain, enhancing 
CBF and preventing regression of cerebrovessels are new therapeutic targets for AD 
according to the neurovascular hypothesis.  
 The differentiation of AD from vascular dementia (VD) is hampered by clinical 
diagnostic criteria with lowered sensitivity and specificity. The most frequently examined 
biomarkers in the diagnosis of dementia are cerebrospinal fluid (CSF) tau, phospho-tau 
which is phosphorylated at threonine 181, and Aβ1-42 (de Jong et al. 2006). Studies 
indicate that total tau and IL-6 levels were not significantly different between AD 
patients and VD patients. However, AD patients had higher level of phospho-tau as 
compared to VD patients (Jia et al. 2005). This is also supported by other studies that 
show higher levels of CSF phosphor-tau in AD patients as compared to VD patients 
thereby suggesting that phopho-tau is a valuable diagnostic tool to differentiate between 
AD and VD cases (Hu et al. 2002).  
 
1.2. ROLE OF BRAIN INFLAMMATION IN ALZHEIMER’S DISEASE:  
 The vast majority of AD cases are sporadic with no history of associated 
mutations. In addition to plaques and NFT’s, gliosis is another important feature of AD 
pathology (McGeer and McGeer 2001, McGeer et al. 1989). Microglia the resident 
macrophages of the brain may identify Aβ oligomers or Aβ aggregates as foreign 
material and this recognition may prompt their activation. Activated microglia found in 
and around amyloid plaques are morphologically characterized by short tortuous ramified 
processes (Meda et al. 1995). Astrocytes that become activated in AD brain are 
characterized by morphologically long sinuous processes that reach in and around the 
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amyloid plaque. These cells upregulate glial fibrillary acidic protein (GFAP) the most 
specific marker of astrocytosis. The release of pro-inflammatory molecules accounts for 
the activated astrocytes which express GFAP (Little et al. 2001). Reactive astrocytes 
result in the production of other acute phase reactants such as α-1-antichymotrypsin 
which are found co-localized with fibrillar cores of mature Aβ plaques thereby promoting 
Aβ aggregation (Abraham and Potter 1989). These activated microglia and astrocytes are 
considered to be signs of an inflammatory response in AD brain. The cyclooxygenase 
(COX) enzymes COX-1 and COX-2 responsible for the production of prostaglandins 
(PGs) from the substrate arachidonic acid are also upregulated in regions of the AD brain 
undergoing degeneration supporting the inflammation hypothesis (Masferrer et al. 1995, 
Zhang et al. 1997, Hoozemans et al. 2001). Also, pro-inflammatory cytokines have 
shown to be neurotoxic in vitro at high doses (Meda et al. 1995, Downen et al. 1999).  
Studies reveal that Aβ is responsible for the stimulation and production of pro-
inflammatory eicosanoids and cytokines such as TNFα  in various in vitro models (Paris 
et al. 2000, Lue et al. 1999).  Pro-inflammatory cytokines such as IL-1β, TNFα, IL-6 and 
IL-8 are typically found to be elevated in AD brain compared to non-AD subjects 
(McGeer and McGeer 1999, Lue et al. 2001). IL-6 stimulation in AD brains increases tau 
phosphorylation which further causes neurodegeneration (Quintanilla et al. 2004). IL-6 
cytokine is produced within the CNS by astrocytes and microglia and under normal 
physiologial conditions have a neuroprotectant and neurotrophic role. However, chronic 
exposure of IL-6 causes neurodegeneration (Nelson et al. 2002). Patients with traumatic 
brain injury revealed higher levels of IL-6 and IL-8 (Kushi et al. 2003) suggesting that 
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these cytokines and other chemokines could also serve as potential biomarkers for 
neuroinflammatory diseases such as AD, multiple sclerosis and Parkinson’s disease (Tan 
et al. 2007, Nagatsu et al. 2000).  Converging lines of evidence from epidemiological 
studies, post mortem evaluations and animal models of AD all support the hypothesis that 
chronic inflammation plays a deleterious role in the pathophysiology of AD. Numerous 
epidemiological studies have demonstrated that NSAIDs such as ibuprofen and 
indomethacin significantly reduce the risk for the incidence of AD (McGeer and McGeer 
1999, Imbimbo 2004).  
 TgAPPsw mice develop age dependent gliosis with increasing amyloid levels. 
AD-like pathology is also observed in double transgenic mice with the PS1 M146L 
mutation together with the TgAPPsw mutation (Holcomb et al. 1998, Duff et al. 1996). 
These mice develop gliosis as detected by thioflavin S staining and anti-Aβ antibody 
(Holcomb et al. 1998). Studies with 10 month old TgAPPsw mice treated with ibuprofen 
showed reduced amyloid pathology and decreased microglial activation (Lim et al. 2000). 
Other studies demonstrate that this amyloid lowering property of ibuprofen in transgenic 
mice was due to its ability to reduce Aβ1-42 production by affecting APP processing 
(Yan et al. 2003).  Thus animal models of AD develop not only Aβ deposit pathology but 
also manifest gliosis comparable to that found in AD patient brains. Studies in transgenic 
mouse models of AD particularly suggest that severity of microgliosis is directly 
proportional to Aβ burden. One study showed that high levels of Aβ1-42 rather than 
Aβ1-40 were able to activate microglia more potently as measured by the release of 
TNFα and nitric oxide secretion (Meda et al. 1995).  
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 Although a plethora of research has been carried out on AD, there is to date no 
known cure for this disease and the neurodegeneration is without remission. All 
treatments available on the market today, namely, acetylcholine esterase inhibitors, 
NMDA receptor blockers, anti-inflammatory drugs, antioxidants offer only symptomatic 
relief and slow progression of the disease to some extent (Prasad et al. 2002).  
 
1.3. ROLE OF CALCIUM IN INFLAMMATION AND AD:  
 Altered calcium homeostasis is considered to play an important role in 
neurodegeneration associated with normal aging, AD and related disorders (Mattson 
1992). In vitro studies on cultured neurons with the calcium ionophore A23187 indicated 
that calcium influx resulted in microtubule disruption due to altered tau phosphorylation 
(Mattson et al. 1991). Studies of brain tissue from AD patients reveal increased activation 
of calcium-dependent proteases in neurofibrillary tangles. Abnormalities in calcium 
regulation in astrocytes, oligodendrocytes, and microglia have also been documented in 
experimental models of AD (Mattson and Chan 2003, Nusslein et al. 1996).  
Calcium ion is vital for neuronal signaling and is tightly regulated. Receptor 
mediated changes in intracellular calcium is one of the major pathways involved in signal 
transduction. Calcium mediated signals are generated by four main processes namely 
calcium influx from extracellular spaces across the plasma membrane into the cytoplasm, 
calcium release from internal stores into the cytoplasm, calcium extrusion from 
cytoplasm across the plasma membrane and calcium sequestration into intracellular 
calcium stores (Moller 2002).  Calcium influx across the plasma membrane into the 
cytoplasm occurs via receptor operated channels (ROCs) triggered by ligand binding, 
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voltage gated calcium channels (VGCCs) and calcium permeable store-operated channels 
(SOCs) which open up when intracellular stores of calcium are depleted. VGCCs are a 
group of voltage-gated ion channels found in neurons, glial cells, muscle cells, etc.  
involved in the release of neurotransmitters and hormones, muscular contraction, 
excitability of neurons and gene expression (Dolphin 2006). VGCCs include the neural 
N-type channel blocked by ω-conotoxins, the residual R-type channel involved in 
processes in the brain and muscle, the closely related P/Q-type channel blocked by ω-
agatoxins, and the dihydropyridine-sensitive L-type channels responsible for excitation-
contraction coupling of skeletal, smooth, and cardiac muscle and hormone secretion in 
endocrine cells. The reason I evaluated the effect of L-type calcium channel blockers 
over other type of calcium channel blockers on reducing inflammation was due to studies 
in aging hippocampal or cortical neurons of rodents and rabbits that reveal an increase in 
L-VGCC activity. Their hypothesis is that increased L-VGCC activity drives many of the 
other calcium related biomarkers of hippocampal aging together with ryanodine receptors 
(RyR) (Thiebault et al. 2007). Other studies have demonstrated that the age-related 
learning impairment in rabbits is reversed by the specific L-type calcium channel blocker 
nimodipine thereby suggesting that elevation of L-type channel activity causes neuronal 
dysfunction during aging (Davare and Hell 2003).  
 Studies reveal that pro-inflammatory cytokines like IFNγ and IL-1β induce 
calcium response and cause subsequent activation of microglia (Franciosi et al. 2002, 
Goghari et al. 2000).  Influx of calcium also results in the release of PGs from the 
substrate arachidonic acid, the mediators of inflammation. Our previous data further 
support the hypothesis that Aβ can activate calcium dependent secretory phospholipase 
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A2 (PLA2) resulting in the production of arachidonic acid which is metabolized into 
proinflammatory eicosanoids (Paris et al. 2000). PGE2 induces increases in intracellular 
calcium both in astrocytes and in neurons. The intracellular calcium increase in neurons 
may be mediated by glutamate released from astrocytes (Bezzi et al. 1998). Studies on rat 
hippocampal neurons treated with IL-6 resulted in an increased calcium influx via 
NMDA-receptor, since NMDA receptor antagonists blocked this IL-6 mediated calcium 
influx. Further this increase in cytosolic calcium induced tau protein 
hyperphosphorylation via the JAK/STAT pathway (Orellana et al. 2005). Previous 
studies with chronic exposure of Purkinje neurons to IL-6 reveal similar increases in 
intracellular calcium resulting in neurodegenration (Nelson et al. 2002). Increases in 
intracellular calcium cause activation of microglia and release of cytokines and 
chemokines which are blocked when calcium is chelated (Hoffmann et al. 2003). Hence, 
my rationale was that perhaps calcium channel blockers (CCBs) or inhibitors of the 
calcium signaling pathway could help alleviate inflammation in AD. Several studies in 
patients with cardiovascular disease and hypertension indicate that these CCBs increase 
blood flow, dilate blood vessels, reduce nitric oxide release, which in turn prevents 
oxidative stress and reduces inflammation (Mason et al. 2003, Sudano et al. 2007). 
Clinical studies with Amlodipine, a calcium channel blocker showed reduced risk in the 
development and progression of coronary artherosclerosis on the basis of its anti-oxidant 
and anti-inflammatory properties. Amlodipine caused a reduction of the inflammatory 
chemokine monocyte chemotactic protein-1 (MCP-1) (Kataoka et al. 2004).  
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1.3.1. RATIONALE FOR CALCIUM CHANNEL BLOCKERS BEHAVING AS 
ANTI-INFLAMMATORY AGENTS 
 Our previous studies in transgenic mouse models of AD have shown that Aβ 
causes vasoconstriction of cerebral blood vessels and is also responsible for stimulating 
Cox-2 activity resulting in the production of pro-inflammatory eicosanoids (Paris et al. 
2003). This Aβ mediated vasoactivity can be alleviated by using calcium channel 
blockers both in vitro and in vivo (Paris et al. 2004). I also showed that organotypic brain 
slice cultures from TgAPPsw mice over 9 months produced significant levels of TNFα 
and Cox-2 activity. These mice had significant amyloid pathology and when brain slices 
of these mice were treated with a selective Cox-2 inhibitor NS-398, levels of TNFα was 
significantly reduced (Quadros et al. 2003).  Aβ has been shown to cause synaptic 
dysfunction and can render neurons vulnerable to excitotoxicity and apoptosis by a 
mechanism involving disruption of cellular calcium homeostasis (Mattson et al. 1992).  
Since it has been well established that inflammation and alteration in cellular calcium 
levels are some of the factors responsible for the pathogenesis in AD, I hypothesized that 
there could be a link between altered calcium levels and inflammation. My hypothesis 
was that Aβ could mediate inflammation by possibly altering cellular calcium levels. I 
also wanted to identify which conformation of Aβ was most potent in mediating 
inflammation in glial cells and correlate this pro-inflammatory effect to altered calcium 
levels.  My other aim was to determine the effect of the various conformations of 
Aβ with respect to neurodegeneration and evaluate if this Aβ mediated neurotoxicity 
could be blocked by using calcium channel blockers or other inhibitors that are part of the 
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calcium signaling pathway. The other inhibitors of the calcium signaling pathway include 
nuclear factor-kappa B (NFkB) inhibitors, phospholipase C (PLC) inhibitors, protein 
kinase C (PKC) inhibitors and calmodulin kinase inhibitors. These inhibitors could 
possibly have anti-inflammatory effects with Aβ induced inflammation because of their 
property of reducing intracellular calcium. In vitro studies on neurons have shown that 
calcium is responsible for the stimulation of NFkB activity (Lilienbaum and Israel 2003). 
Other studies revealed that NFkB activity could be significantly reduced by using PKC or 
calmodulin kinase inhibitors (Bonizzi et al. 1999, Han and Logsdon 2000). Both PKC 
kinase and calmodulin kinase are activated by calcium entry into the cytosol which 
further activates NFkB activity in neurons (Lilienbaum and Israel 2003). Evidence from 
earlier studies reveals that NFkB activation causes inflammation (Hata et al. 2002, Granet 
et al. 2003).  In addition, calcium channel blockers like amlodipine have shown to behave 
as anti-inflammatory agents in rat models of arteriosclerosis (Kataoka et al. 2004, Yoshii 
et al. 2006). Other studies on amlodipine reveal that it exerts protective vascular effects 
by probably suppressing pro-inflammatory cytokines and free radical generation (Chou et 
al. 2002, Richard 2005). Other calcium channel blockers more specifically the 
dihydropyridines such as nitrendipine, manidipine including amlodipine have also 
demonstrated anti-inflammatory properties with respect to other inflammatory diseases 
such as multiple sclerosis, experimental autoimmune encephalomyelitis (Toba et al. 
2005, Brand-Schieber and Werner 2004). Hence my rationale that calcium channel 
blockers and other inhibitors of the calcium signaling pathway could have potential anti-
inflammatory effects in human glial cells thereby protecting neurons from the pathogenic 
inflammatory insults mediated by Aβ in AD.  
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CHAPTER TWO 
 
Increased TNFα Production and Cox-2 Activity in Organotypic Brain 
Slice Cultures from APPsw Transgenic Mice 
 
ABSTRACT 
 
β-amyloid (Aβ) peptides are the principal component of senile plaques and 
vascular deposits in Alzheimer’s disease (AD) and are derived from the proteolytic 
cleavage of the β-amyloid precursor protein (APP). I have previously shown that 
synthetic Aβ can stimulate cyclooxygenase-2 (Cox-2) activity in brain organotypic slice 
cultures. In the present study, I used brain slices from transgenic APP Swedish 
(TgAPPsw) mice and control littermates of different age groups to determine the effect of 
APP overexpression on the levels of prostaglandin and TNFα release. The production of 
eicosanoid and TNFα was increased as a function of age in organotypic brain slice 
culture from TgAPPsw mice compared to age matched control littermates. I also showed 
that the selective Cox-2 inhibitor NS-398 reduces the production of eicosanoid and 
TNFα in organotypic brain slice cultures of TgAPPsw mice. In conclusion, my data 
suggest that either activity or expression of Cox-2 is increased in TgAPPsw mice brains 
as a function of age, contributing to an increased production of pro-inflammatory 
eicosanoids and TNFα.  
 
 
 
Keywords: Alzheimer’s disease, inflammation, Cox-2, TgAPPsw mice, PGE2, TNFα 
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INTRODUCTION:  
 Alzheimer’s disease (AD) is a neurodegenerative disease characterized by 
extracellular Aβ deposits and intracellular neurofibrillary tangles (Wilcock and Esiri 
1982). AD is a multifactorial disease, of which neuroinflammation is suggested to be one 
of the major contributing factors in the progression of the disease (Bamberger and 
Landreth 2002, Eikelenboom et al. 2002). This is evidenced by the upregulation of both 
cyclooxygenase (Cox) enzymes, Cox-1 and Cox-2 in AD brain (Ho et al. 2001) and by 
the fact that several epidemiological studies have revealed that non-steroidal anti-
inflammatory drugs (NSAIDs) reduce the risk for developing AD (McGeer and McGeer 
1998). NSAIDs block Cox-1 and Cox-2 that are responsible for the production of 
prostaglandins (Dannhardt and Kiefer 2001). Cerebral amyloid plaques in AD patients 
are co-localized with activated microglia and astrocytes. Several reports have revealed 
that activated microglia and astrocytes release eicosanoids and cytokines that may 
contribute to the inflammatory response observed in AD brains (Vehmas et al. 2003).  
We have shown previously in organotypic rat brain slices, that synthetic Aβ peptide can 
stimulate the production of prostaglandin E2 (PGE2) and TNFα via a Cox-2 dependent 
manner (Paris et al. 2002). Aβ progressively accumulates in the brains of transgenic mice 
overexpressing APP with the Swedish mutation (TgAPPsw line 2576). Before 9 months 
of age, no β-amyloid plaque can be observed in the brain of these animals, after 9 months 
the amount of Aβ deposits increase with age (Kuo et al. 2001).  
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METHODS:  
 1 mm thick brain slices were sectioned using a mouse brain slicer from TgAPPsw 
and control animals at different ages  (3 month, 10 month, 14 month, 17 month) and 
cultured in neurobasal media supplemented with 5% B27 (Gibco-Invitrogen, CA) and 
Penicillin-Streptomycin-Fungizone mixture. The levels of PGE2 (Fig. 1) and TNFα 
(Fig.2) that accumulate in the culture medium surrounding the brain slices after 24 h 
incubation at 37°C was measured using ELISA kits (Biosource, CA).  
 
RESULTS:  
 No difference in the accumulation of PGE2 and TNFα were observed between 3 
month-old TgAPPsw and control organotypic brain slice cultures. An increased 
accumulation of both PGE2 and TNFα was observed in TgAPPsw brain slice cultures 
compared to control brain slices cultures isolated from 10, 14 and 17 month-old animals. 
To determine whether the increased production of PGE2 were dependent on COX-2 
activity, I treated the brain slices with 20 µM of the selective COX-2 inhibitor NS-398. 
NS-398 completely inhibited the increased production of PGE2 (Fig. 3) in 14 M 
TgAPPsw brain slice culture compared to control cultures suggesting that the increased 
PGE2 production observed is mediated by COX-2. Interestingly, NS-398 also partially 
alleviated the increased TNFα production observed in organotypic brain slice culture 
from TgAPPsw mice (Fig. 4).   
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DISCUSSION:  
 Microgliosis and astrocytosis are known to be associated with β-amyloid deposits 
in the brain of TgAPPsw mice (Gasic-Milenkovic et al. 2003) and in vitro, activated 
microglia and astrocytes are known to produce eicosanoids and TNFα (Casal et al. 2002).  
My data suggest that the increased production of PGE2 and TNFα by organotypic brain 
slice cultures from TgAPPsw mice older than 9 months may be related to the glial 
reaction occurring in the brain of TgAPPsw mice. The fact that the selective Cox-2 
inhibitor NS-398 was able to reduce TNFα levels suggests that metabolites of the Cox-2 
pathway are also important for regulating TNFα release. TNFα is a cytokine produced in 
response to inflammation and brain injury by astrocytes and microglia (Lee et al. 2000). 
Studies in transgenic and knockout mouse models of TNFα have revealed that this 
cytokine plays a dual role in the brain (Probert et al. 1997). TNFα can be both protective 
and damaging depending on the levels produced and the duration of action (Pober 1987). 
Increased levels of TNFα activate microglia resulting in the production of additional 
cytokines that may cause neurodegeneration (Neumann et al. 2002). Altogether my data 
show that the brains of TgAPPsw mice are subjected to inflammatory stress with aging 
leading to increased Cox-2 activity and TNFα production. We have previously shown in 
vitro using rat brain slices that synthetic Aβ is capable of inducing the production of pro-
inflammatory cytokines and TNFα  (Paris et al 2002).  My results using organotypic 
brain slice cultures from TgAPPsw and control littermates reveal a progressive 
stimulation of Cox-2 activity and TNF-α production in function of age. Products of the 
Cox-2 enzyme are known to play a role in long-term potentiation (LTP) in hippocampal 
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neurons and postsynaptic membrane excitability (Chen et al. 2002) suggesting that a 
stimulation of Cox-2 activity by Aβ may impair neuronal functions and affect learning 
and memory. My data support the fact that there is an active inflammatory process 
occurring in the brain of TgAPPsw mice. The fact that young TgAPPsw mice do not 
show this inflammatory condition suggests that inflammation parallels the accumulation 
of Aβ in the brain and might be associated with gliosis. Moreover, my data demonstrate 
that the use of selective Cox-2 inhibitors can block the increased PGE2 release observed 
in TgAPPsw brain slices suggesting that Cox-2 activity is upregulated in the brain of 
TgAPPsw mice.  Metabolites of the arachidonic acid cascade are important mediators of 
LTP and neuronal plasticity; the abnormal stimulation of Cox-2 activity observed may 
therefore lead to impaired neuronal function. Besides, other studies with TNFα suggest 
that, through activation of the transcription factor NF-kappaB, TNFα may modulate 
neuronal excitability and vulnerability to excitotoxicity (Furukawa and Mattson 1998). 
My data demonstrate that the selective Cox-2 inhibitor NS-398 can also reduce TNFα 
levels significantly. Ηence, blocking Cox-2 enzyme activity by using selective Cox-2 
inhibitors may be efficient at reducing neuroinflammatory events occurring in AD brains.  
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Figure 1: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1: PGE2 release in culture media surrounding 3M, 14M, 17M old control and TgAPP 
sw mice brain slices. ANOVA revealed significant main effect of age (p<0.001), of 
transgenicity (p<0.001), interactivity between age and transgenicity (p<0.001). Post-hoc 
analysis showed significant differences in PGE2 levels between control and TgAPP sw 
17M of age brain slice culture media. 
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Figure 2: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2: TNFα levels in culture media surrounding 3M, 10M, 14M and 17M old control 
and TgAPP sw mice brain slices. ANOVA revealed significant main effect of age 
(p<0.009), main effect of transgenicity (p<0.001) and an interactivity between them 
(p<0.009). Post-hoc analysis revealed significant differences in TNFα production 
between control 14M & TgAPP 14M (p<0.009) as well as significance difference 
between control 17M & TgAPP 17M (p<0.05). 
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Figure 3: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3: PGE2 release in culture media surrounding 14M old brain slices of control and 
TgAPP sw mice treated with and without 20µM NS398. ANOVA revealed significant 
main effect of transgenicity (p=0.038), a main effect of NS398 (p<0.001) as well as 
interactivity between NS398 and transgenicity (p<0.001). Post-hoc analysis showed 
significant differences between PGE2 production in control cortex & TgAPP cortex but 
no significant differences between control cortex & TgAPP cortex & between NS398 and 
TgAPP cortex (p=0.4) showing that NS398 completely inhibits the production of PGE2 in 
TgAPP brain slice. 
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Figure 4: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4:  TNFα levels in culture media surrounding 14M old brain slices of control and 
TgAPPsw mice treated with and without 20µM NS398.  ANOVA revealed significant 
main effect of NS398 (p<0.04), main effect of transgenicity (p<0.001) as well as 
interactivity between the two (p<0.04). Post-hoc analysis revealed significant difference 
in TNFα production between control and TgAPPsw cortex (p<0.001). Hence, NS398 
inhibits TNFα production by TgAPP sw brain slice. 
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CHAPTER THREE 
Increase of calcium entry by Aβ promotes inflammation in human  
      astrocytes and microglia 
 
ABSTRACT: 
BACKGROUND: Aβ has been shown to cause synaptic dysfunction and can render 
neurons vulnerable to excitotoxicity and apoptosis by a mechanism involving disruption 
of cellular calcium homeostasis. Studies have shown that an increase in intracellular 
calcium plays an important role in the activation of glia and in the propagation of 
inflammatory reactions in the CNS. My aim was to identify whether Aβ could affect 
calcium entry in human astrocytes and microglia and whether a correlation between 
calcium dysregulation and the pro-inflammatory effect of Aβ could be established.  My 
data show that high molecular weight oligomers (HMWO) of Aβ1−42 stimulate calcium 
entry in microglia and astrocytes more potently than low molecular weight oligomers 
(LMWO) of Aβ1−42 or preparations of freshly solubilized (FS) Aβ containing essentially 
dimeric forms of the peptide. In addition, I show that the HMWO forms of Aβ are more 
potent at stimulating inflammation in astrocytes and microglia than LMWO Aβ or FSAβ.  
METHODS: Primary culture of human astrocytes and microglia were used to determine 
the impact of the various forms of Aβ (FS, LMWO, HMWO) on calcium entry and on the 
levels of pro- inflammatory cytokines IL-6 and IL-8. The production of cytokines was 
quantified using Bio-plex cytokine profiling assay while calcium entry in the cells was 
monitored fluorimetrically.  
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RESULTS: My results indicate that HMWO Aβ are more potent than LMWO or FSAβ at 
stimulating IL-6 and IL-8 levels in human astrocytes and microglia. The increase in pro-
inflammatory cytokines induced by the oligomeric species of Aβ is inhibited by the 
intracellular chelator BAPTA-AM. The HMWO are more potent at stimulating IL-6 and 
IL-8 in astrocytes and microglia than LMWO Aβ or FSAβ. In addition, HMWO are also 
more potent than FSAβ at stimulating calcium entry in human astrocytes and microglia.  
CONCLUSION: My data therefore suggests a link between the inflammatory effect of 
Aβ oligomeric species and their effect on calcium entry in human astrocytes and 
microglia.  
 
BACKGROUND: 
Several studies have revealed that cytokines serve as powerful regulators of glial cell 
function and contribute to CNS pathology. Studies have shown that an increase in 
intracellular calcium plays an important role in the production of cytokines by glia 
resulting in the propagation of inflammatory reactions in the CNS (Hoffmann et al. 
2003). Although in principle, glial activation aims at CNS protection, excessive or 
sustained activation could significantly contribute to acute and chronic neuropathologies. 
Dysregulation of glial cytokine production could therefore disturb neural cell functions 
and result in neurotoxicity (Benveniste 1998, Benveniste et al. 2001). In AD, soluble Aβ 
comprises mainly of monomeric/dimeric and oligomeric species, whereas, insoluble Aβ 
consists of aggregated forms  which are the major components of senile plaques. Studies 
in rodent hippocampus reveal that soluble Aβ  mediates an inhibition of LTP, resulting in 
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memory loss (Rowan et al. 2005). My aims were to identify which form of Aβ1−42 (FS, 
LMWO, HMWO) are most potent in activating microglia and astrocytes, as well as 
determine if this effect of Aβ is mediated in part by an alteration of intracellular calcium 
levels. Pro-inflammatory cytokines have been shown to induce calcium response and 
activate glial cells in experimental models of AD (Mattson et al. 1997, Goghari et al. 
2000). In the present study I compared the effects of the various forms of Aβ1-42 on 
calcium entry and their corresponding impact on the levels of pro-inflammatory 
cytokines.  
 
METHODS AND MATERIALS:  
Preparation of the different forms of Aβ1-42:  
Freshly solubilized: Lyophilized Aβ1-42 peptide (Purity greater than 95%, Biosource, 
CA) was dissolved to 1 mg/ml in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) (Sigma-
Aldrich, MO) in order to minimize formation of β-sheet structures and promote α-helical 
secondary structure. Aβ1-42 was allowed to air dry in a chemical fume hood for 1h, 
followed by further drying in a speed-vac for 30 minutes. The resulting clear film was re-
suspended in 100% DMSO to a concentration of 1mM. Peptides were subsequently 
aliquoted and stored at -80°C.  LMWO: An aliquot of the DMSO stock of Aβ1-42 was 
diluted to 100 µM in HBSS (Invitrogen, CA) not containing calcium and incubated 
overnight at 4ºC. The peptide was then centrifuged at 16,000g for 30 mins at 4ºC. The 
supernatent (containing LMW Aβ species) was collected and dissolved to appropriate 
concentration in HBSS. HMWO: HFIP treated Aβ1-42 was diluted in DMSO to 100µM 
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in PBS and incubating for 5 days at 37ºC. HMWO were pelleted by centrifugation at 
15,000g for 15 mins and resuspended in HBSS. Aβ1-42 concentrations in the different 
preparations were estimated by using Aβ1-42 ELISA (Biosource, CA) after denaturing 
the different forms of Aβ with 80% formic acid. In addition, the different preparations of 
Aβ were evaluated on native and denaturing conditions using 4-20% gradient PAGE 
followed by electroblotting on Polyvinylidene fluoride (PVDF) membranes and 
immunodetection with the antibody 4G8 (Signet laboratories).  
 
Cell culture: Primary cultures of human astrocytes and human microglia (ScienCell, MD) 
were cultured in astrocyte medium and microglia media respectively (ScienCell, MD) 
supplemented with 10% fetal bovine serum, astrocyte growth medium/microglia growth 
medium and 1X Penicillin-Streptomycin-Fungizone mixture (Cambrex Corp., NJ). The 
treatment groups included various forms (FS, LMWO, HMWO) of Aβ1-42 at 1µM. Cells 
were also treated with 10µM of the calcium ionophore A23187 (Sigma-Aldrich, MO), 
20µM of the intracellular calcium chelator BAPTA-AM (Sigma-Aldrich, MO), a PLC 
inhibitor, U73122 (Sigma-Aldrich, MO) at 10µM, a calmodulin kinase inhibitor KN62 
(Sigma-Aldrich, MO) at 5µM  and a L-type calcium channel blocker Nilvadipine 
(Fujisawa, Japan) at 5µM.  Cell culture plates were incubated at 37°C and culture media 
collected 24h after treatment. IL-6 and IL-8 were quantified in the culture medium using 
the Luminex fluorescent-bead-based technology (de Jager et al. 2003, Patel et al. 2005). 
Human cytokine 2-plex panel kits (Bio-Rad, CA) were used according to the 
recommendation of the manufacturer.  
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Measurement of intracellular calcium levels: Intracellular calcium levels were evaluated 
by spectrofluorometry using Fluo-4 (Molecular Probes). Human astrocytes and microglia 
were grown on a black costar 96-well plates previously coated with collagen for 24 hrs. 
Confluent cells were treated with 5µM of Fluo-4 in DMEM for 30 minutes in a cell 
culture incubator. Cells were subsequently washed in DMEM followed by 3 washes in 
HBSS containing no calcium in order to remove any unincorporated Fluo-4. Intracellular 
calcium levels were quantified using a Bio-tek spectrofluorometer equipped with two 
plate microinjectors (Bio-tek Inc., VT) at specific excitation (485 nm) and emission (516 
nm) wavelengths. Baseline intracellular calcium levels were continuously recorded for 1 
minute. Immediately following treatment of the cells with 1µM FS, LMWO and HMWO 
Aβ1−42,  intracytoplasmic calcium was continuously recorded for one minute to 
determine the possible impact of the different forms of Aβ on calcium release by 
intracellular calcium stores. Finally, following one minute of treatment with different 
forms of Aβ, 2mM of CaCl2 was added to the cells and intracellular calcium levels were 
continuously monitored for another minute in order to evaluate the impact of the different 
forms of Aβ on calcium entry. 
 
Statistical analyses 
For statistical analyses, ANOVA followed by post-hoc analysis using Bonferroni were 
performed using SPSS for Windows release 10.1. Results are represented as Mean +/- 
SEM.  
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RESULTS:  
Analysis and evaluation of the different soluble forms of Aβ1-42: 
FS, LMWO and HMWO Aβ1-42 loaded on a 4-20% gradient PAGE under non-
denaturing conditions revealed that HFIP treated FS Aβ displayed tetramers in addition to 
dimers on immunodetection, LMWO Aβ prepared by aging HFIP Aβ for 24h at 4°C was 
detected as a band at 20kd and HMWO Aβ prepared by aging HFIP Aβ for 5 days at 
37°C revealed a large band comprising of the different forms of Aβ, more specifically the 
large oligomers >90kd. Under denaturing conditions (Tris/gylcine/SDS), 
immunodetection with the monoclonal antibody 4G8 showed that FSAβ formed a band at 
around 4kd, LMWO bands were detected at 20kd while HMWO formed a large band at 
around 70kd indicating that oligomers are SDS resistant (Fig.1).  
 
Effect of HMWO, LMWO and FS Aβ1-42 on calcium influx in human astrocytes and 
microglia: 
Data show that HMWO, LMWO and FSAβ1-42 tested do not have any major impact on 
the release of calcium by internal stores following one minute of treatment in human 
astrocytes and microglia in calcium-free HBSS (Fig. 2a, 2c). However, following 
addition of extracellular calcium in microglia and astrocytes, calcium entry was 
differentially stimulated by HMWO, LMWO and FS Aβ1-42. Interestingly, HMWO and 
LMWO of Aβ1-42 appear more potent than FSAβ at stimulating calcium entry in 
astrocytes and microglia. Mean peak amplitude of calcium entry was quantified for the 
three forms of Aβ1-42 (Fig. 2b, 2d).  
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Effect of HMWO, LMWO and FS Aβ1-42 on the production of IL-6 and IL-8 in human 
astrocytes and microglia:  
Levels of IL-6 and IL-8 were quantified in media collected from human astrocytes and 
microglia following 24h treatment with HMWO, LMWO and FS Aβ1-42. Pro-
inflammatory cytokines IL-6 and IL-8 were elevated in both astrocytes and microglia 
following treatment with the HMWO as compared to control and FSAβ (Fig.3a-3d) 
Levels of IL-6 and IL-8 in microglia were slightly increased by LMWO compared to 
control and FSAβ (Fig. 3b, 3d).  IL-8 levels in astrocytes were slightly increased by 
LMWO as compared to control and FSAβ (Fig 3c). 
 
Effect of A23187 and BAPTA-AM on the release of IL-6 and IL-8 by human astrocytes 
and microglia:  
The calcium ionophore A23187 significantly increased IL-6 and IL-8 levels, whereas the 
intracellular calcium chelator BAPTA-AM reduced basal cytokine production of IL-6 and 
IL-8 in both astrocytes and microglia (Fig 4a-4d) showing that the production of IL-6 and 
IL-8 by microglia and astrocytes is dependent on intracellular calcium levels.  
 
Effect of HMWO Aβ1-42 on IL-6 and IL-8 production by human astrocytes and microglia 
after co-treatment with the other calcium signaling inhibitor and Nilvadipine, the L-type 
calcium channel blocker:  
After establishing that the HMWO Aβ1-42 is most potent in stimulating both IL-6 and 
IL-8 in astrocytes and microglia, we wanted to determine if Nilvadipine (the L-type 
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calcium channel blocker), U73122 (a PLC inhibitor) and KN62 (a calmodulin kinase 
inhibitor) could inhibit or reduce levels of these pro-inflammatory molecules stimulated 
by 1µM HMWO Aβ1-42. My results demonstrated that 5µM Nilvadipine significantly 
reduces the production of both IL-6 and IL-8 mediated by 1µM HMWO Aβ in both 
astrocytes and microglia (Fig.5a-5d), suggesting that Aβ mediates the production of IL-6 
and IL-8 in astrocytes and microglia  by stimulating calcium entry via L-type calcium 
channels. My results also revealed a significant reduction in both IL-6 and IL-8 in 
astrocytes and microglia following treatment with 10µM U73122 and 5µM KN62 (Fig. 
5a-5d), strongly suggesting that compounds affecting calcium signaling pathways can 
have anti-inflammatory properties. 
 
DISCUSSION:  
 Activation of glia resulting in the production of pro-inflammatory cytokines is a 
feature observed in mouse models of AD and in pathological tissue samples from AD 
patients (Tarkowski et al. 2003, Patel et al. 2005). My previous studies with brain slices 
from TgAPPsw mice reveal that Aβ causes an increase in pro-inflammatory cytokines 
(Quadros 2003). Several studies have shown that dysregulation of calcium homeostasis 
and/or increases in intracellular levels of calcium are also responsible for the activation of 
glia and in the propagation of inflammatory reactions in the CNS (Hoffmann et al. 2003, 
Mattson and Chan 2003). Evidence from various studies reveal that intracellular calcium 
stimulates the release of pro-inflammatory cytokine IL-6 and chemokine IL-8 in human 
mast cells via activation of NFkB (Kim et al. 2005, Mitsuyama et al. 2004, Kempuraj et 
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al. 2003). Studies in human microglia treated with IL-8 reveal that it enhances Aβ1-42 to 
release other pro-inflammatory cytokines and increases the activity of COX-2 resulting in 
the production of eicosanoids (Franciosi et al. 2005). My aim was to determine which 
particular forms of Aβ1-42 differentially affect calcium influx in glial cells and to 
determine to what extent this increase of calcium influx in glial cells mediates the 
production of the major proinflammatory cytokines IL-6 and IL-8. I observed that 
HMWO Aβ 1-42 is more potent than FS or LMWO at increasing calcium influx and 
cytokine production in both astrocytes and microglia. To further demonstrate that Aβ 
induced increases in pro-inflammatory interleukins IL-6 and IL-8 was dependent on 
increased intracellular levels of calcium, I used BAPTA-AM, an intracellular calcium 
chelator. My results demonstrated that the intracellular calcium chelator BAPTA-AM can 
oppose cytokine production triggered by HMWO and LMWO Aβ1-42 suggesting that 
calcium increases induced by Aβ is necessary to promote the proinflammatory action of 
Aβ.  Interestingly, I also observed that FSAβ1-42 was not a potent stimulus for 
increasing pro-inflammatory levels of IL-6 and IL-8 and was also not able to increase 
intracellular calcium levels. 
 In addition, both astrocytes and microglia produced elevated levels of both IL-6 
and IL-8 in response to the calcium ionophore A23187. The elevated levels of IL-6 and 
IL-8 were reduced by treatment with Nilvadipine, U73122, and  KN62. Studies on rat 
astrocytes have revealed that PLC stimulates the production of IL-6 in response to 
endothelins (Morga et al. 2000). Other studies on astrocytes have shown that a pro-
inflammatory stimulus can induce the production of IL-6 via activation of the NFkB by 
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calmodulin kinase enzyme (Schwaninger et al. 1999). Therefore, my data in glial cells 
treated with oligomeric forms of Aβ suggest that blocking calcium entry either by 
blocking L-type channels or by inhibiting PLC (which regulates intracellular calcium 
stores) or by inhibiting calmodulin kinase may be of interest for preventing glial 
activation in AD patients. Several reports indicate that calcium channel blockers used for 
the treatment of hypertension can lower the risk of developing dementia, including AD 
(Forette et al. 2002, Menne et al. 2006). Studies indicate that the brain loses its ability to 
downregulate intracellular levels of calcium with age (Toescu et al. 2004) and the 
reduced risk of dementia associated with calcium channel blockers is presumed to be 
related to their ability to prevent excess entry of calcium into neurons (Trompet et al. 
2006). The relationship between glial activation and neurodegeneration remains unclear, 
although several cytokines and inflammatory mediators produced by activated microglia 
and astrocytes have the potential to initiate or exacerbate the progression of 
neuropathology in several CNS disorders. Hence, my data suggest that changes in 
intracellular levels of calcium mediated by oligomeric forms of Aβ1-42 (mainly HMWO) 
may be responsible for the activation of glial cells in AD. Neuroinflammation is a 
prominent feature of AD pathology as evidenced by astrogliosis and microgliosis 
reported in various studies (Akiyama et al. 1999, Akiyama et al. 2000). Recent studies 
using primary cultures of human astrocytes demonstrate that Aβ mediated increases in 
NFkB activity further stimulate inflammation, activating glial cells resulting in the 
production of more Aβ via activation of BACE 1 enzyme (Bourne et al. 2007). The 
reason HMWO Aβ are more potent than LMWO and FSAβ in stimulating calcium influx 
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and cytokine release may be due to the fact that HMWO Aβ contains more β-sheet than 
the other two forms. Studies on neurons have indicated that neurotoxicity mediated by 
Aβ is related to the β-sheet content of the peptide (Watson et al. 2005). Our results 
indicate that the inflammation mediated by HMWO Aβ is caused by an increase in 
intracellular calcium levels, which can be blocked by using Nilvadipine. Calmodulin 
kinase inhibitors decrease the production of IL-6 and IL-8 in astrocytes and microglia by 
inhibiting intracellular calcium signaling. Our results strongly suggest that compounds 
that modulate calcium influx in glial cells decrease inflammation and therefore can be 
neuroprotective. Further studies on human neuronal cells need to be performed to 
determine the effect of these calcium channel blockers on HMWO Aβ1-42 mediated 
neurotoxicity.   
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Figure 5:  
 
 
Fig. 5: Western blot of Aβ1-42 using 4G8 monoclonal antibody under denaturing and 
non-denaturing conditions. FS, LMWO and HMWO Aβ1-42 loaded on a 4-20% gradient 
PAGE under denaturing conditions (Tris/gylcine/SDS) followed by electroblotting on 
PVDF and immunodetection with the monoclonal antibody 4G8 showed that FSAβ 
formed a band at around 4kd, LMWO bands were detected at 20kd while HMWO formed 
a large band at around 70kd.  
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Figure 6a: Astrocytes 
 
 
 
 
 
 
 
 
 
 
 
Figure 6b: Astrocytes 
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Figure 6c: Microglia 
 
 
 
 
 
 
 
 
 
 
 
Figure 6d: Microglia 
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Fig. 6: a) Real time measurement of calcium entry in human astrocytes following 
treatment with FS, LMWO and HMWO Aβ1-42 at 1µM dose (n=6 for each treatment 
group). b) Quantification of intracellular calcium entry in human astrocytes. ANOVA 
revealed significant main effects between control and HMWO, control and LMWO and 
control and FSAβ in astrocytes. Post-hoc analysis by Bonferroni showed significant 
effect of all three treatment groups (p<0.05). c) Real time measurement of calcium entry 
in human microglia following treatment with FS, LMWO and HMWO Aβ1-42 at 1µM 
dose (n=6 for each treatment group). d) Quantification of intracellular calcium entry in 
human microglia. ANOVA followed by post-hoc analysis showed significant main 
effects between control and HMWO, control and LMWO (p<0.05) but no significant 
difference between control and FSAβ in microglia (p>0.05).  
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Figure 7a: Astrocytes        
 
 
 
 
 
 
 
 
 
 
 
Figure 7b: Microglia 
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Figure 7c: Astrocytes 
 
 
 
 
 
 
 
 
 
 
 
Figure 7d: Microglia 
 
 
 
 
 
 
 
 
 
 
IL
-
8p
g/
m
l 
IL
-
8p
g/
m
l 
0
100
200
300
400
500
600
700
800
900
Control FSAb 1uM HMWO 1uM LMWO 1uM
*
*
*
0
500
1000
1500
2000
2500
3000
3500
Control FS Aß 1µM HMWO 1µM LMWO 1µM
*
   
 63   
Fig. 7: a) Bar graph of IL-6 levels in media after 24h following treatment with FS, 
LMWO and HMWO Aβ1-42 at 1µM dose (n=6 for each treatment group) in astrocytes. 
ANOVA followed by post-hoc analysis revealed significant main effects between control 
and HMWO (p<0.05) but no significant difference between control and LMWO 
(p>0.05). b)  Bar graph of IL-6 levels in media after 24h following treatment with FS, 
LMWO and HMWO Aβ1-42 at 1µM dose (n=6 for each treatment group) in microglia. 
ANOVA followed by post-hoc analysis revealed significant main effects between control 
and HMWO (p<0.05) but no significant difference between control and LMWO or FSAβ 
(p>0.05). c) Bar graph of IL-8 levels in media after 24h following treatment with FS, 
LMWO and HMWO Aβ1-42 at 1µM dose (n=6 for each treatment group) in astrocytes. 
ANOVA followed by post-hoc analysis revealed significant main effects between control 
and HMWO (p<0.05) but no significant difference between control and LMWO, and 
control or FSAβ (p>0.05). d)  Bar graph of IL-8 levels in media after 24h following 
treatment with FS, LMWO and HMWO Aβ1-42 at 1µM dose (n=6 for each treatment 
group) in microglia. ANOVA followed by post-hoc analysis revealed significant main 
effects between control and HMWO (p<0.01) but no significant difference between 
control and LMWO or FSAβ (p>0.01). 
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Figure 8a:  Astrocytes       
 
 
 
 
 
 
 
 
 
 
 
Figure 8b: Microglia       
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Figure 8c: Astrocytes 
 
 
 
 
 
 
 
 
 
 
Figure 8d: Microglia 
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Fig. 8: a & c) Bar graph of IL-6 and IL-8 levels in media after 24h following treatment 
with 10µM A23187, 20µM BAPTA-AM and control (untreated cells) in astrocytes (n=6 
for each treatment group). ANOVA followed by post-hoc analysis revealed significant 
main effects between control and A23187 (p<0.05), control and BAPTA-AM (p<0.05) 
and A23187 and BAPTA-AM (p<0.05) for IL-6 and IL-8. b& d)  Bar graph of IL-6 and 
IL-8 levels in media after 24h following treatment with 10µM A23187, 20µM BAPTA-
AM and control (untreated cells)  in microglia (n=6 for each treatment group). ANOVA 
followed by post-hoc analysis revealed significant main effects between control and 
A23187 (p<0.05), control and BAPTA-AM (p<0.05), A23187 and BAPTA-AM (p<0.05) 
for both IL-6 and IL-8.  
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Figure 9a:  Astrocytes  
 
 
 
 
 
 
 
 
 
 
 
Figure 9b: Microglia 
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Figure 9c: Astrocytes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9d: Microglia 
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Fig. 9: a & c) Bar graph of IL-6 and IL-8 levels in media after 24h following treatment 
with HMWO Aβ1-42 at 1µM, 5µM Nilvadipine alone, 10µM U73122 alone, 5µM KN62 
alone and in combination respectively (n=6 for each treatment group) in astrocytes. 
ANOVA followed by post-hoc analysis revealed significant main effects between control 
and HMWO (p<0.05), HMWO and HMWO + Nilva (p<0.01), HMWO and HMWO + 
U73122 (p<0.01), HMWO and HMWO + KN62 (p<0.01) for both IL-6 and IL-8. b& d)  
Bar graph of IL-6 and IL-8 levels in media after 24h following treatment with HMWO 
Aβ1-42 at 1µM, 5µM Nilvadipine alone 10µM U73122 alone, 5µM KN62 alone and in 
combination respectively (n=6 for each treatment group) in microglia. ANOVA followed 
by post-hoc analysis revealed significant main effects between control and HMWO 
(p<0.05), HMWO and HMWO + Nilva (p<0.05), HMWO and HMWO + U73122 
(p<0.05), HMWO and HMWO + KN62 (p<0.05) for IL-6 and IL-8.  
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    CHAPTER FOUR  
Effect of calcium channel blockers on Aβ induced neurodegeneration in  
    human neurons 
ABSTRACT:   
 Abnormalities in calcium ion homeostasis have been linked to the neurotoxic 
effects of Aβ.  My previous data with human as trocyes and microglia reveal that high 
molecular weight oligomers (HMWO) of Aβ1-42 increased the release of pro-
inflammatory cytokines by stimulating calcium entry via L-type calcium channels and 
phospholipase C activation. My aim was to identify if HMWO Aβ could also increase 
inflammation in human neuronal precursor cells (HNPCs) via modulation of calcium 
influx in HNPCs.  In addition, I also wanted to determine the neurotoxic effect of 
HMWO Aβ and elucidate if this neurotoxic effect could be mitigated by using L-type 
calcium channel blockers and other inhibitors involved in the calcium signaling pathway 
such as calmodulin kinase II inhibitors.  My data show that HMWO Aβ significantly 
increased inflammation and neurotoxicity by stimulating calcium entry by L-type calcium 
channels.  My results further demonstrate that the pro-inflammatory and neurotoxic effect 
of HMWO Aβ can be blocked by using calmodulin kinase II inhibitors further suggesting 
that HMWO Aβ mediated inflammation and neurotoxicity is calcium dependent. 
Interestingly, I also observed reduction of calcium entry in HNPCs by anti-inflammatory 
agents suggesting that there is a link between inflammation and altered calcium influx 
resulting in subsequent neurodegeneration. 
Keywords: human neuronal precursor cells, calcium channel blockers, calmodulin kinase 
II inhibitors, and inflammation  
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 Alzheimer’s disease (AD) which is characterized by abnormal accumulation of 
beta-amyloid (Aβ) peptide in the brain is thought to be responsible for the 
neurodegeneration associated with AD. However, the mechanisms that contribute to 
neuronal degeneration in AD are not fully understood. Altered calcium homeostasis is 
considered to be one of the mechanisms involved in the neurodegeneration associated 
with normal aging, AD and related disorders (Thibault 2007). Studies with hippocampal 
neurons treated with aggregated Aβ peptide undergo neurodegeneration by a mechanism 
involving an increase in intracellular calcium levels (Mattson 2007). In vitro studies on 
cultured neurons with the calcium ionophore A23187 indicated that calcium influx 
resulted in microtubule disruption due to altered tau phosphorylation (Mattson 1992). In 
our present study we evaluated which conformation of Aβ was most toxic to human 
neuronal precursor cells (HNPC). I have previously established that HMWO Aβ were 
most potent in increasing intracellular calcium influx in glial cells and this same 
conformation was also able to induce the production of proinflammatory IL-6 and IL-8 
(Quadros 2007). Elevated levels of IL-6 and IL-8 are found in the brain of mild cognitive 
impaired (MCI) patients as well as traumatic brain injury (TBI) patients  as compared to 
non-MCI and non-TBI subjects (Magaki 2007, Kushi 2003).  Elevated levels of IL-6 
have also been reported in AD patients (Nelson 2001). Hence, I wanted to determine 
whether HMWO Aβ were responsible for the disruption of neurons via inflammation 
through a mechanism involving an increase in intracellular levels of calcium. Based on 
our previous results with glial cells our hypothesis for the mechanism involved in 
HMWO Aβ mediated increase in calcium entry was that Aβ may be affecting the activity 
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of L-type calcium channels or other calcium signaling pathways (Figure 1). To support 
my hypothesis I used Nilvadipine (a selective L-type calcium channel blocker) and KN62 
(a calmodulin kinase II inhibitor). My rationale for using KN62 was because calmodulin 
kinase II is activated when intracellular calcium levels are elevated. I also wanted to 
determine if there was a link between altered levels of intracellular calcium and 
inflammation, so we treated HNPCs with Ibuprofen (a NSAID) and NS-398 (a selective 
COX-2 inhibitor).  
 
EXPERIMENTAL PROCEDURES:  
Preparation of the different forms of Aβ1-42:  
The different conformations of Aβ1−42 peptide were prepared as per the protocol listed 
in the previous chapter.  
 
Cell culture of HNPC: 
Primary culture of HNPCs (Clonexpress Inc., MD) was cultured in DMEM/F12 media 
(Invitrogen, CA) supplemented with 5% fetal bovine serum (Invitrogen, CA), 10ng/ml 
basic fibroblast growth factor (Sigma-Aldrich, MO), 10ng/ml epidermal growth factor 
(Sigma-Aldrich, MO), 1X neuronal cell supplement (Clonexpress Inc., MD) and 1X 
Penicillin-Streptomycin-Fungizone mixture (Cambrex Corp., NJ). The treatment groups 
included 1µM of freshly solubilized (FS), low molecular weight oligomers (LMWO), and 
HMWO forms of Aβ1-42. The other treatments include 5µM Nilvadipine (Fujisawa, 
Japan), 5µM NS-398, 25µM Ibuprofen, 5µM KN62 (Sigma-Aldrich, MO) and the 
various combination treatments along with control (cells treated with vehicle only). The 
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cell culture plates were incubated at 37°C and media from these plates was collected after 
24h of treatment and tested for cytokine profiling using human cytokine 2-plex panel kits 
(Bio-Rad, CA) according to the recommendation of the manufacturer. 
 
Measurement of intracellular calcium levels:  
HNPC’s were grown on a poly-L-lysine coated black costar 96-well plate for 24 hrs. 
Confluent cells were treated with 5µM of Fluo-4 (Molecular Probes) in DMEM for 30 
minutes at 37°C in a cell culture incubator. Cells were subsequently washed in DMEM 
followed by 3 washes in calcium-free HBSS in order to remove any unincorporated Fluo-
4. Intracellular calcium levels were quantified using a Bio-tek spectrofluorometer 
equipped with two plate microinjectors (Bio-tek Inc., VT) at specific excitation (485 nm) 
and emission (516 nm) wavelengths. Baseline intracellular calcium levels were 
continuously recorded for 1minute every 1/100 second. Immediately following treatment 
of the cells with 1µM FS, LMWO and HMWO Aβ1-42,  intracytoplasmic calcium was 
continuously recorded for one minute to determine the impact of the different forms of 
Aβ on calcium release by intracellular calcium stores. Finally, following one minute of 
treatment with different forms of Aβ, 2mM of CaCl2 was added extracellularly to the 
culture medium and intracellular calcium levels were continuously monitored in order to 
evaluate the impact of the different forms of Aβ on calcium entry. 
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Measurement of neurotoxicity induced by Aβ on HNPC:  
HNPC cells were grown on a 24 well plate with the HMWO Aβ1−42  alone and at a dose 
of 20µM and in combination with Nilvadipine 5µM, 5µM NS398, 25µM Ibuprofen, and 
5µM KN62 over a period of 4 days. The neurotoxicity mediated by HMWO Aβ was 
monitored at different time points 24h, 48h 72h and 96h by using the Scion Image 
software at 10X and 20X magnification. Media was collected at the end of 96h and LDH 
was performed on the media and cell lysate to evaluate the level of toxicity mediated by 
the various conformations of Aβ1-42. 
 
Statistical analyses 
For statistical analyses, ANOVA and t-tests were performed where appropriate using 
SPSS for Windows release 10.1. Results are represented as Mean +/- SEM. Post-hoc 
analysis was conducted using Bonferroni  p<0.05 or p<0.01. 
 
RESULTS:  
Effect of FS, LMWO and HMWO Aβ1−42  on the release of IL-6 and IL-8 in HNPCs:  
 
Media from HNPC collected after 24h was used to measure the levels of IL-6 and IL-8 
following treatment with 1µM FS, LMWO, and HMWO Aβ1-42. Levels of both pro-
inflammatory cytokines IL-6 and IL-8 were significantly elevated following treatment 
with the HMWO Aβ as compared to FS Aβ and LMWO Aβ (Fig 2a & 2b).  
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Effect of HMWO Aβ1−42  on the release of IL-6 and IL-8 in HNPCs after co-treatment 
with calmodulin kinase II inhibitor and the L-type calcium channel blocker:  
After establishing that HMWO Aβ1-42 is most potent in stimulating both IL-6 and IL-8 
in HNPCs, I wanted to determine if Nilvadipine (a selective L-type calcium channel 
blocker), and KN62 (a calmodulin kinase II inhibitor) could inhibit or reduce levels of 
these pro-inflammatory molecules stimulated by 1µM HMWO Aβ1-42. My results 
demonstrated that 5µM Nilvadipine significantly reduces the production of both IL-6 and 
IL-8 mediated by 1µM HMWO Aβ in HNPCs (Fig.3a, 3b), suggesting that Aβ mediates 
the production of IL-6 and IL-8 in astrocytes and microglia by stimulating calcium entry 
via L-type calcium channels. My results also revealed a significant reduction in both IL-6 
and IL-8 in astrocytes and microglia following treatment with  5µM KN62 (Fig. 3a, 3b), 
strongly suggesting that compounds affecting calcium entry and calcium signaling 
pathways can oppose the pro-inflammatory effect of HMWO Aβ on HNPCs. 
 
Intracellular levels of calcium in HNPC following HMWO Aβ stimulation and in 
combination with Nilvadipine, Ibuprofen and NS398:  
My results demonstrate that HNPCs showed an increase in intracellular calcium influx 
with 20µM HMWO Aβ1-42 and this increase in calcium influx mediated by HMWO Aβ 
is blocked significantly by 5µM Nilvadipine (Fig. 4a & 4b), 5µM NS398 (Fig.5a &5b) 
and 25µM Ibuprofen (Fig.6a & 6b) suggesting that inflammation stimulates calcium 
influx which can be blocked by using anti-inflammatory agents.  
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Effect of calcium antagonists and anti-inflammatory agents on HMWO Aβ1-42 mediated 
neurotoxicity of HNPCs: 
My results with HNPC’s grown for a period of 4 days after treatment with 20µM HMWO 
Aβ and in conjunction with 5µM Nilvadipine, 5µM KN62, 5µM NS398 and 25µM 
Ibuprofen reveal that the neurodegeneration induced by HMWO Aβ was significantly 
reduced by 5µM Nilvadipine, 5µM KN62 (Fig. 7a), 5µM NS398, 25µM Ibuprofen (Fig. 
7b) even after 96h. The LDH levels were measured after 96h and our results indicate that 
the amount of LDH released by the HMWO Aβ was significantly higher as compared to 
HNPCs co-treated with HMWO and Nilvadipine, KN62, NS-398, and Ibuprofen 
respectively (Fig. 8). My data suggest that these compounds may either have a direct 
neuroprotective effect or prevent neurodegeneration by reducing inflammation via 
modulation of intracellular calcium levels. 
 
DISCUSSION:  
 Several studies suggest that Aβ may cause neurodegeneration in AD (Rasool 
1986, Chiarini 2006). However, different conformations of Aβ have different effects on 
the pathophysiology of AD resulting in a cascade of events (Deshpande 2006, Standridge 
2006). I used primary HNPCs to elucidate the effect of the various conformations of Aβ 
on neurotoxicity. My other aim was to determine if this neurotoxic effect of Aβ was 
mediated by an increase in intracellular calcium levels. My previous studies with human 
astrocytes and microglia revealed that HMWO and to some extent LMWO increased 
intracellular levels of calcium more than FS Aβ1-42. This is supported by other studies 
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on hippocampal neurons revealing that Aβ 1-42 oligomers are more toxic to neurons than 
the fibrillar or monmeric/dimeric species (De Felice 2004). The oligomeric 
conformations significantly increased the release of pro-inflammatory interleukins IL-6 
and IL-8 via modulation of calcium influx as previously seen in glial cells. Furthermore, 
my results with HNPC reveal that HMWO Aβ are toxic to neurons, and this neurotoxicity 
is mitigated by using 5µM Nilvadipine suggesting that HMWO Aβ increases the activity 
of L-type VGCC in neurons. The neurotoxic effect of HMWO Aβ  was also blocked by 
using 5µM KN62 thereby suggesting that the neurotoxic effect is calcium dependent. It 
has been demonstrated that calmodulin kinase inhibitors reduce NFkB activity in neurons 
(Lilienbaum 2003). My previous results in astrocytes and microglia treated with 
Nilvadipine and KN62, reveal that these compounds reduce the production of IL-6 and 
IL-8 induced by HMWO Aβ1-42 (previous chapter). This suggests that the 
neuroprotective effect mediated by these compounds on HNPCs maybe due to their 
ability to decrease the pro-inflammatory effect of HMWO Aβ by modulating calcium 
entry. To further demonstrate a link between altered calcium levels and inflammation in 
mediating neurotoxicity of HNPCs I used two anti-inflammatory agents Ibuprofen and 
NS398 together with HMWO Aβ1-42 and showed that even after 96h there was very 
little neurodegeneration ( Fig. 7b). My results with these two anti-inflammatory agents on 
calcium influx indicated that they significanty reduced calcium entry in HNPCs 
following treatment with HMWO Aβ (Fig.5 and 6). Altogether my data suggest that 
elevated intracellular levels of calcium mediated by oligomeric forms of Aβ1-42 promote 
the release of pro-inflammatory cytokines and chemokines in human neurons. This highly 
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elevated load of inflammatory cytokines and chemokines is responsible for the 
neurodegeneration associated in AD patients (Griffin 1998) and hence blocking 
inflammation by modulating intracellular levels of calcium could have potential 
therapeutic implications in various neuroinflammatory diseases including multiple 
sclerosis, Parkinson’s disease, AIDS etc.   
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Figure 10: Proposed hypothesis for Aβ mediated neurotoxicity. 
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Figure 11a: IL-6 levels in HNPCs 
 
 
 
 
 
 
 
 
 
 
 
Figure 11b: IL-8 levels in HNPCs 
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Fig. 11: a) Bar graph of IL-6 levels in media following 24h treatment with 1µM FS, 
LMWO, HMWO Aβ1-42 and Control (n=6 for each treatment group) in HNPCs. 
ANOVA followed by post-hoc analysis revealed significant differences between control 
and HMWO (p<0.05), FSAβ and HMWO (p<0.05), LMWO and HMWO (p<0.05). 
 b)  Bar graph of IL-8 levels in media following 24h treatment with 1µM FS, LMWO, 
HMWO Aβ1-42 and Control (n=6 for each treatment group) in HNPCs. ANOVA 
followed by post-hoc analysis revealed significant differences between control and 
HMWO (p<0.05), FSAβ and HMWO (p<0.05), LMWO and HMWO (p<0.05).  
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Figure 12a: IL-6 levels in HNPCs 
 
 
 
 
 
 
 
 
 
 
Figure 12b: IL-8 levels in HNPCs 
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Fig. 12: a) Bar graph of IL-6 levels in media after 24h following treatment with 5µM 
Nilvadipine, 1µM HMWO Aβ1-42, 1µM HMWO + 5µM Nilvadipine, 5µM KN62, and 
1µM HMWO + 5µM KN62 and Control (n=6 for each treatment group) in HNPCs. 
ANOVA followed by post-hoc analysis revealed significant differences between control 
and HMWO, HMWO and HMWO + Nilvadipine (p<0.05), HMWO and HMWO + KN62 
 b)  Bar graph of IL-8 levels in media after 24h following treatment with 5µM 
Nilvadipine, 1µM HMWO Aβ1-42, 1 µM HMWO + 5µM Nilva, 5µM KN62, and 1µM 
HMWO + 5µM KN62 and Control (n=6 for each treatment group) in HNPCs. ANOVA 
followed by post-hoc analysis revealed significant differences between Control and 
HMWO, HMWO and HMWO + Nilvadipine, HMWO and HMWO + KN62 (p<0.05).  
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Figures 13a & 13b: Calcium entry in HNPC following treatment with Nilva 
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Fig. 13: a) Fluorometric measurement of calcium entry in human HNPCs following 
treatment with 20µM HMWO Aβ1-42, 5µM Nilvadipine, HMWO + Nilvadipine (n=6 for 
each treatment group). b) Quantification of intracellular calcium entry in HNPCs 
following the above mentioned treatments. ANOVA followed by post-hoc analysis 
revealed significant differences between control and HMWO (p<0.05), HMWO and 
HMWO + Nilvadipine (p<0.05).  
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Figures 14a & 14b: Calcium entry in HNPC following treatment with NS-398 
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Fig. 14: a) Real time measurement of calcium entry in human HNPCs following 
treatment with 20µM HMWO Aβ1-42, 5µM NS398, HMWO + NS398 (n=6 for each 
treatment group). b) Quantification of intracellular calcium entry in HNPCs following the 
above mentioned treatments. ANOVA followed by post-hoc analysis revealed significant 
main effects between control and HMWO (p<0.05), HMWO and HMWO + NS398 
(p<0.05).  
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Figures 15a & 15b: Calcium entry in HNPC following treatment with Ibuprofen 
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Fig. 15: a) Real time measurement of calcium entry in human HNPCs following 
treatment with 20µM HMWO Aβ1-42, 25µM Ibuprofen, HMWO + Ibuprofen (n=6 for 
each treatment group). b) Quantification of intracellular calcium entry in HNPCs 
following the above mentioned treatments. ANOVA followed by post-hoc analysis 
revealed significant main effects between control and HMWO (p<0.05), HMWO and 
HMWO + Ibuprofen (p<0.05).  
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Figure 16: HNPC cells using 20X magnification – Day 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 16: Neurotoxicity observed in HNPCs following treatment with 20µM HMWO Aβ1-
42 alone and in combination with 5µM Nilvadipine and 5µM KN62 after 96h as recorded 
using the Scion software imager at 20X magnification. 
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Figure 17: HNPC cells using 10X magnification – Day 4  
  
 
 
 
 
 
 
 
 
 
 
      
 
 
 
 
 
Fig. 17: Neurotoxicity observed in HNPCs following treatment with 20µM HMWO Aβ1-
42 alone and in combination with 5µM NS-398 and 25µM Ibuprofen after 96h as 
recorded using the Scion software imager at 10X magnification.  
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Fig. 18: LDH in HNPCs  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 18: LDH ratio of media versus lysate of HNPCs after treatment with 20µM HMWO 
Aβ1-42 alone and in combination with 5µM Nilvadipine, 5µM KN62, 5µM NS-398, 
25µM Ibuprofen after 96h. ANOVA followed by post-hoc analysis revealed significant 
main effects between control and HMWO (p<0.05), HMWO and HMWO + Nilvadipine 
(p<0.05), HMWO and HMWO + KN62 (p<0.05), HMWO and HMWO + NS-398 
(p<0.05), HMWO and HMWO + Ibuprofen (p<0.05). 
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              CHAPTER FIVE 
     DISCUSSION and CONCLUSIONS 
DISCUSSION:   
 My previous studies and several other reports have established that Aβ causes 
inflammation which is evident by increased activation/expression of Cox-2 enzyme (Paris 
et al 2002, Quadros et al 2003), activation of astrocytes and microglia in response to Aβ 
deposition (Sastre et al 2006). Other evidence supporting that inflammation is one of the 
pathogenic factors involved in AD is based on epidemiological studies with NSAIDs 
which show protective effects with long-term intake in AD patients (McGeer and 
McGeer 2007, Stewart et al 1997). Aβ which is derived from its substrate APP assumes 
different conformations capable of assuming different biological activities. Several earlier 
reports differentiated Aβ as soluble and aggregated forms and the soluble forms of Aβ 
were demonstrated to be more pathogenic in AD (Mclean et al 1999). Subsequent studies 
by atomic force microscopy revealed that the soluble pool of Aβ consisted of 
monomers/dimers and oligomers (Mastrangelo et al 2006). I have tried to determine 
which conformation of Aβ1−42 is most toxic to neurons by correlating its toxicity to 
inflammation in glial cells and its subsequent effect on neurons. My results demonstrate 
that Aβ1−42 in its monomer/dimer form also referred to as freshly solubilized (FS) is not 
toxic to neurons nor does it stimulate inflammation as observed by the release of 
interleukins IL-6 and IL-8 in astrocytes and microglia.  However oligomeric forms of 
Aβ, more specifically the high molecular weight oligomers (HMWO) as opposed to the 
low molecular weight oligomers (LMWO) are more toxic to neurons and also produce 
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significantly higher levels of proinflammatory IL-6 and IL-8 in both astrocytes and 
microglia (Quadros chapter 3). IL-6 and IL-8 are both pro-inflammatory molecules found 
to be elevated in the brains of patients with diseases such as AD, mild cognitive 
impairment (MCI) and traumatic brain injury (TBI) (McGeer and McGeer 1999, Lue et al 
2001, Kushi et al 2003). Studies in rat cortical neurons reveal that Aβ together with IL-6 
activate NMDA receptors resulting in neuronal damage (Quiz and Gruol 2003, Conroy et 
al 2004). Similar studies in rat neurons with IL-8 treatment resulted in neurotoxicity via 
increase in the release of neurotoxins and pro-apoptotic proteins (Thirumangalakudi et al 
2007).  
 The other part of my thesis was to determine if excess influx of calcium into cells 
is responsible for the inflammation observed in AD. It is well established that in AD there 
is a dysregulation of calcium within the cells (Mattson and Chan 2003). Recent reports 
have shown that calcium accelerates the change in conformation of Aβ (Isaacs et al 2006) 
and this change from soluble to oligomeric forms is probably responsible for the 
neurotoxicity observed in AD (Hartley et al 1999, Watson et al 2005). In addition, 
increase in cytosolic calcium also affects APP processing in rat cortical neurons resulting 
in an increase in intraneuronal production of Aβ1-42 (Pierrot et al 2004). But I wanted to 
correlate this increase in intracellular calcium mediated by Aβ with increases in 
inflammation. My results with astrocytes and microglia demonstrate that oligomeric 
forms of Aβ (more specifically HMWO Aβ) that increased IL-6 and IL-8 were also the 
most potent form in increasing intracellular levels of calcium within these cells. This 
proinflammatory effect mediated by calcium was blocked when an intracellular calcium 
chelator BAPTA-AM was used and conversely was potentiated significantly with the 
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calcium ionophore A23187. Hence my results strongly suggest that blocking increased 
intracellular levels of calcium could reduce inflammation mediated by activated glia in 
response to Aβ. Acute inflammation is neuroprotective in nature, however chronic 
inflammation is neurotoxic. My hypothesis was that L-type calcium channel blockers and 
other inhibitors of the calcium signaling pathway like NFkB inhibitors and calmodulin 
kinase inhibitors could block Aβ mediated inflammation via modulation of calcium 
inside the cell. The reason I chose L-type calcium channel blockers over other types of 
voltage gated calcium channel blockers such as N, P/Q, and R was because of previous in 
vitro studies on neurons indicating an increase in L-type calcium channel activity 
following exposure to beta amyloid (Ekinci et al 1999, Ho et al 2001). Hence blocking L-
type calcium channels would reduce inflammation in glia and decrease 
neurodegeneration which is supported by my results shown on glia and HNPCs (Quadros 
et al. 2007, chapter 4).  L-type calcium channel blockers and calmodulin kinase inhibitors 
could therefore act as dual antagonists of inflammation and calcium influx and possibly 
have potential therapeutic effects not only in AD but also in other neuroinflammatory 
diseases like multiple sclerosis, Parkinson’s disease, TBI etc. Studies in rat cortical 
neurons revealed that L-type calcium channel blockers reduced neuronal apoptosis 
mediated by activation of spla2 enzyme (Yagami et al 2004). My results with known 
anti-inflammatory agents NS-398, a selective COX-2 inhibitor and Ibuprofen, a NSAID 
reveal significant reduction in neuronal loss even after day 4 compared to control and 
HMWO Aβ1-42.  Both NS-398 and Ibuprofen were capable of inhibiting the effect of 
HMWO Aβ mediated neurodegeneration. Similar effects were observed with 
Nilvadipine, the L-type calcium channel blocker and KN62, the calmodulin kinase 
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inhibitor. Interestingly, both known anti-inflammatory agents NS-398 and Ibuprofen 
were capable of reducing the increased calcium influx in human neuronal precursor cells 
(HNPCs) mediated by HMWO Aβ1-42 thereby suggesting that there is a correlation 
between calcium influx and inflammation.  
 
CONCLUSIONS: 
 It is well established that several etiological factors are responsible for the 
pathogenesis in AD. However, my hypothesis was that there is a connection between 
excess calcium influx into glial cells and inflammation in AD. Regulating excess calcium 
influx in glial cells would decrease subsequent activation of these cells from releasing 
proinflammatory cytokines and chemokines which could be toxic to neurons. Several 
reports on astrocytes indicate that Aβ mediated toxicity on neurons is via changes in 
intracellular levels of calcium (Abramov et al 2003, Monnerie et al 2005).  My results 
with Nilvadipine, the L-type calcium channel blocker, and KN62, a calmodulin kinase 
inhibitor reveal that blocking excess levels of intracellular calcium in HNPCs mediated 
by HMWO Aβ and to some extent LMWO Aβ may be responsible for the attenuation of 
neurotoxicity observed in these cells. Calmodulin kinase and NFkB are actively involved 
in the regulation of calcium signaling across cells (Lin et al 2004, Choi et al 2006).  
Studies with NFkB inhibitors demonstrate that they have anti-inflammatory effects 
(Lopez-Franco et al 2006, Lopez-Franco et al 2002). My data with L-type calcium 
channel blocker and calmodulin kinase inhibitor on glial cells reveal that they reduce the 
production of IL-6 and IL-8 which are both pro-inflammatory thereby suggesting that 
increase in intracellular calcium causes inflammation. The reason these inhibitors 
   
 103   
mitigate neurotoxicity in HNPCs could be due to reduction in the production of these pro-
inflammatory molecules. To further demonstrate that the neuroprotection offered by these 
calcium channel blockers or inhibitors associated with calcium binding were as a result of 
their anti-inflammatory effect, I used anti-inflammatory agents such as NS-398, a Cox-2 
inhibitor and Ibuprofen , an NSAID on HNPCs. Previous studies with Ibuprofen on 
TgAPPsw mice early in the course of the disease reveal that it reduced amyloid 
deposition and the treatment also reduced activation of microglia around plaques 
resulting in a subsequent reduction in dystrophic neurites (Lim et al 2000, Heneka et al 
2005).  Reports indicate that increased Cox-2 activity caused neuronal damage in primary 
cortical neurons when induced by LPS and iron (Im et al 2006). My results with 
Ibuprofen and NS-398 reveal significant reduction in neurotoxicity mediated by HMWO 
Aβ. Another interesting result is that these anti-inflammatory agents (NS-398 and 
Ibuprofen) were capable of inhibiting the increase in calcium influx mediated by HMWO 
Aβ. This suggests that there is a correlation between inflammation and calcium influx 
and my results further indicate that HMWO Aβ1−42  are most potent than 
monomers/dimers or fibrillar forms in mediating inflammation via disruption of 
intracellular calcium levels and causing neurotoxicity to cells. Hence, modulating 
intracellular calcium levels by using calcium channel blockers or calmodulin kinase 
inhibitors may reduce HMWO Aβ mediated chronic inflammation in glial cells and 
protect neurons in AD patients.  
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